Brief: Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
20/11/2023 13:37
Nov 20 (Reuters) - Alpha Tau Medical Ltd DRTS.O :
* ALPHA TAU SUBMITS TO JAPANESE PMDA FOR PRE-MARKET APPROVAL
OF
ALPHA DART IN PATIENTS WITH RECURRENT HEAD AND NECK CANCER
Source text for Eikon: ID:nGNXq1XkL
Further company coverage: DRTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer